Trial Profile

A pivotal study of XP-8121 for the treatment of adults with hypothyroidism

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 May 2025 According to a Xeris Biopharma Holdings media release, company announced its first in-person and virtual analyst and investor day in New York City on Tues, Jun 3, 2025, at 10:00 a.m. EST, key opinion leaders (KOLs) Antonio C. Bianco, MD, PhD (University of Texas Medical Branch), Francesco S. Celi, MD, MHSc (UConn Health), and Eliza B. Geer, MD (Memorial Sloan Kettering Cancer Center), to discuss Phase 3-ready, once-weekly, subcutaneous injection for treating hypothyroidism.
03 Jun 2024 New trial record
30 May 2024 According to a Xeris Biopharma Holdings media release, FDA End-of-Phase 2 interaction to facilitate a Phase 3 pivotal study program is expected by year-end.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com